Cardinal Health Inc, a provider of products and services supporting the health care industry, announced May 23 that it has completed the acquisition of Denver Biomedical Inc, a designer and manufacturer of specialized medical products for chronic fluid management in the chest and abdomen. Terms of the agreement were not disclosed.
Based in Golden, Colo, Denver Biomedical has 50 employees and markets specialty drainage products worldwide for hospital and home use, primarily for terminally-ill cancer patients. Founded in 1969, Denver Biomedical’s products include the Pleurx® pleural catheter system and the Denver® pleural effusion shunt. Denver Biomedical was the first company to receive FDA clearance specifically for an indwelling catheter for drainage of chronic pleural and ascitic fluids.
“Well recognized by clinicians, Denver Biomedical’s products are a great fit with our existing business,” said Tom Daulton, VP and general manager, special procedures, Cardinal Health.
Headquartered in Dublin, Ohio, and ranked number 19 on the Fortune 500, Cardinal Health employs more than 55,000 people on six continents and manufactures and markets a full range of devices used in biopsy and spine procedures.